Capital Asset Advisory Services’s Ginkgo Bioworks DNA Stock Holding History

Capital Asset Advisory Services’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-1,063	Closed	-$74.4K	–	316
2023 Q3	$74.4K	Hold	1,063	–	–	0.01%	308
2023 Q2	$86.7K	Hold	1,063	–	–	0.01%	331
2023 Q1	$56.5K	Hold	1,063	–	–	﹤0.01%	348
2022 Q4	$71.8K	Hold	1,063	–	–	0.01%	363
2022 Q3	$133K	Hold	1,063	–	–	0.02%	315
2022 Q2	$101K	Hold	1,063	–	–	0.01%	397
2022 Q1	$171K	Sell	1,063 -12	-1%	-$2.34K	0.02%	392
2021 Q4	$357K	Buy	+1,075	New	+$511K	0.04%	300

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACG

Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital Asset Advisory Services's DNA Position: Q4 2023 in Review

Capital Asset Advisory Services sold out of Ginkgo Bioworks (DNA) in Q4 2023, closing a stake of 1,063 shares — an estimated $74.4K sold.

Capital Asset Advisory Services first reported a position in DNA in Q4 2021 and held it in 8 quarters. The position peaked at $357K in Q4 2021. 342 funds tracked by Wall St. Rank hold DNA as of Q4 2023.

Capital Asset Advisory Services reported no remaining Ginkgo Bioworks position as of Q4 2023 after selling out during the quarter.
Capital Asset Advisory Services sold 1,063 Ginkgo Bioworks shares in Q4 2023, an estimated $74.4K.
Capital Asset Advisory Services first reported a position in Ginkgo Bioworks in Q4 2021 and held it in 8 quarters.
Capital Asset Advisory Services's Ginkgo Bioworks position peaked at $357K in Q4 2021.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2023.

Based on Capital Asset Advisory Services's 13F filing for Q4 2023, filed 9 Jan 2024.